ValueScreener

ValueScreener company report

Teleflex Incorporated (TFX)

NYSE / Healthcare / Medical - Instruments & Supplies

Share price

128.22 USD Market dataClose of Oct 15, 2026

Market capitalisation

5.43B USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Feb 27, 2026
Ratios computed
Oct 15, 2026
Filed years
17, FY2008 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

-29.0% Computed

From the FY2025 filing

Read quality

Valuation

Price to book

1.84x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

0.03% Computed

FY2025 accounts, priced at the latest close

Read cash generation

Revenue and net income, as filed

FY2016 Revenue: 1.87B USDFY2016 Net income: 237.4M USDFY2017 Revenue: 2.15B USDFY2017 Net income: 152.5M USDFY2018 Revenue: 2.45B USDFY2018 Net income: 200.8M USDFY2019 Revenue: 2.60B USDFY2019 Net income: 461.5M USDFY2020 Revenue: 2.54B USDFY2020 Net income: 335.3M USDFY2021 Revenue: 2.81B USDFY2021 Net income: 485.4M USDFY2022 Revenue: 2.79B USDFY2022 Net income: 363.1M USDFY2023 Revenue: 1.71B USDFY2023 Net income: 356.3M USDFY2024 Revenue: 1.70B USDFY2024 Net income: 69.7M USDFY2025 Revenue: 1.99B USDFY2025 Net income: -905.6M USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
0 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on equity was -29.0% in FY2025, in the band labelled "Likely below the cost of equity" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on shareholders' money below the usual cost of equity.

Today, against the Medical - Instruments & Supplies industry (51 companies), -29.0% sits at the 30th percentile; the middle half of that group runs from -47.7% to 8.8%.

Is it safe

Interest coverage was 1.18x in FY2025, in the band labelled "Distress territory" (below 1.50x), on lines anchored on Damodaran's interest-coverage table, suggesting an interest bill operating profit barely covers.

Year by year against peers
Whether Teleflex Incorporated's return on equity stayed above the median of the Medical - Instruments & Supplies industry, year by year. (FY2016 to FY2025, 10 fiscal years of Teleflex Incorporated with a comparable figure)
The direction
Which way Teleflex Incorporated's return on equity has moved, and how steadily. (FY2016 to FY2025, 10 filed years of Teleflex Incorporated)
What could explain it
What in Teleflex Incorporated's filed statements could explain the movements. (8 readings drawn from the statement lines Teleflex Incorporated filed)
What to check next
What to check next on Teleflex Incorporated, and where in its filings. (5 questions for Teleflex Incorporated)
In one paragraph
One paragraph on Teleflex Incorporated's returns, cash, balance sheet and price. (13 of sixteen figures read for Teleflex Incorporated)

These are TFX’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research TFXPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Feb 27, 2026, accession 0000096943-26-000019.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

Teleflex Incorporated: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The filed income tax is outside 0 to 100% of pre-tax income (a tax benefit on a profit, a charge on a loss, or a charge above the profit), which is a one-off in the tax line and not a rate operating profit was taxed at, so after-tax operating profit is not computed.

n/a ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Return on equity-29.0% ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Return on capital employed, pre-tax1.9% ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Return on assets-13.0% ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Gross margin56.2% ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Operating margin5.9% ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Net margin-45.5% ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
TFX -45.5%
ICUI 0.0%HAE 7.3%BLCO -7.1%PLSE -20794.6%ATRC -2.1%
-20794.6%7.3%
Net margin: TFX against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

Teleflex Incorporated: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity0.91 ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Current ratio2.54 ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Quick ratio2.01 ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Interest coverage1.18x ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Altman Z-score2.08 ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Net debt2.46B ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Total assets 6.95BTotal liabilities 3.82BShareholders' equity 3.12BOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What Teleflex Incorporated owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Feb 27, 2026, 0000096943-26-000019).

Teleflex Incorporated: balance sheet position
Total assets6.95B FiledFY2025 10-K, filed Feb 27, 2026
Total liabilities3.82B FiledFY2025 10-K, filed Feb 27, 2026
Shareholders' equity3.12B FiledFY2025 10-K, filed Feb 27, 2026
Cash378.6M FiledFY2025 10-K, filed Feb 27, 2026
Total debt2.84B FiledFY2025 10-K, filed Feb 27, 2026
Net debt2.46B
Current ratio2.54
Debt to equity0.91

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

Teleflex Incorporated: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
P/E on trailing twelve months28.94x ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book1.84x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Price to sales2.88x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Enterprise value to EBIT69.20x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Enterprise value to EBITDA27.67x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Diluted earnings per share-20.25 USD FiledFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019

We publish no fair value or price target of our own. Value TFX on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for Teleflex Incorporated today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

Teleflex Incorporated: valuation
Share price128.22 USD
Market capitalisation5.43B USD
Enterprise value to EBITDA27.67x
Graham numbern/m
Diluted earnings per share, FY2025-20.25 USD

Price to earnings on trailing twelve months, a different basis from the fiscal-year P/E above, since Oct 3, 2016: low 17.37x, median 37.80x, high 197.57x, latest 28.94x. 2,287 trading days with a meaningful ratio, 233 more on a loss and left out. Each close over the trailing twelve months of earnings as known that day: a quarter counts from the day it was filed.

Companies like Teleflex Incorporated

  1. ICU Medical, Inc. (ICUI)Market cap 4.18B USD
  2. Haemonetics Corporation (HAE)Market cap 5.52B USD
  3. Bausch + Lomb Corporation (BLCO)Market cap 5.95B USD
  4. Pulse Biosciences, Inc. (PLSE)Market cap 3.25B USD
  5. AtriCure, Inc. (ATRC)Market cap 2.94B USD

Same industry (Medical - Instruments & Supplies) and size band (Mid, 2B to 10B), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

Teleflex Incorporated: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield0.03% ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Free cash flow1.4M USD ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Free cash flow margin0.1% ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Dividend yield1.1% ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
FY2016 Free cash flow: 357.5M USDFY2016 Net income: 237.4M USDFY2017 Free cash flow: 355.4M USDFY2017 Net income: 152.5M USDFY2018 Free cash flow: 354.3M USDFY2018 Net income: 200.8M USDFY2019 Free cash flow: 334.4M USDFY2019 Net income: 461.5M USDFY2020 Free cash flow: 346.4M USDFY2020 Net income: 335.3M USDFY2021 Free cash flow: 580.5M USDFY2021 Net income: 485.4M USDFY2022 Free cash flow: 263.6M USDFY2022 Net income: 363.1M USDFY2023 Free cash flow: 159.7M USDFY2023 Net income: 356.3M USDFY2024 Free cash flow: 211.4M USDFY2024 Net income: 69.7M USDFY2025 Free cash flow: 1.4M USDFY2025 Net income: -905.6M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

Teleflex Incorporated: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
1.84xFY2025Oct 15, 2026
69.20xFY2025Oct 15, 2026
0.03%FY2025Oct 15, 2026
n/aFY2025Feb 27, 2026
n/a The filed income tax is outside 0 to 100% of pre-tax income (a tax benefit on a profit, a charge on a loss, or a charge above the profit), which is a one-off in the tax line and not a rate operating profit was taxed at, so after-tax operating profit is not computed.
1.1%FY2025Oct 15, 2026
0.91FY2025Feb 27, 2026
2.54FY2025Feb 27, 2026
2.88xFY2025Oct 15, 2026
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
2.08FY2025Oct 15, 2026
-2.15FY2025Feb 27, 2026
5/9FY2025Feb 27, 2026

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 17 filed fiscal years on record, FY2008 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2016 to FY2025, read from the annual reports Teleflex Incorporated filed with the SEC. Each year names its filing. Amounts in USD, as filed.

Teleflex Incorporated: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY20251.99B118.4M-905.6M-20.251.4M5.9%-29.0%10-K, Feb 27, 20260000096943-26-000019
FY20241.70B103.7M69.7M1.48211.4M6.1%1.6%10-K, Feb 28, 20250000096943-25-000031
FY20231.71B258.7M356.3M7.53159.7M15.1%8.0%10-K, Feb 23, 20240000096943-24-000036
FY20222.79B499.7M363.1M7.68263.6M17.9%9.0%10-K, Feb 23, 20230000096943-23-000024
FY20212.81B628.1M485.4M10.23580.5M22.4%12.9%10-K, Mar 1, 20220000096943-22-000016
FY20202.54B423.1M335.3M7.09346.4M16.7%10.1%10-K, Feb 25, 20210000096943-21-000013
FY20192.60B427.3M461.5M9.80334.4M16.5%15.5%10-K, Feb 21, 20200000096943-20-000017
FY20182.45B321.7M200.8M4.29354.3M13.1%7.9%10-K, Feb 21, 20190000096943-19-000021
FY20172.15B372.3M152.5M3.27355.4M17.4%6.3%10-K, Feb 22, 20180000096943-18-000028
FY20161.87B319.5M237.4M4.98357.5M17.1%11.1%10-K, Feb 23, 20170000096943-17-000014
  • Revenue, compound annual growth FY2016 to FY2025: 0.7%
  • Earnings: Earnings was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow, compound annual growth FY2016 to FY2025: -45.8%

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

Teleflex Incorporated: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score-2.15 ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Piotroski F-score5/9 ComputedFY2025 10-K, filed Feb 27, 2026, 0000096943-26-000019
Named tests met0 of 30 Computed
Beta0.59 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 27 not met, 3 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
None of the named tests.
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; Low PEG, low debt (Peter Lynch); High returns and growth; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Dividends and buybacks; Low beta, profitable; Near the 52-week low; Z-score and coverage (Edward Altman); Two thirds of NCAV (Benjamin Graham); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Book or below, low debt (Walter Schloss); Cash-covered dividend; Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC; Cheapest quarter on P/B (David Dreman); Low P/E, growth, yield (John Neff)
Not measured
ROIC at or above WACC; P/E times P/B (Benjamin Graham); Cheapest quarter on P/E (David Dreman). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(8)
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Return on Invested Capital: The filed income tax is outside 0 to 100% of pre-tax income (a tax benefit on a profit, a charge on a loss, or a charge above the profit), which is a one-off in the tax line and not a rate operating profit was taxed at, so after-tax operating profit is not computed.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Price Tangible Book: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by Javier Sanz Alvarez: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 8 figures could not be read on this company, among them P/E Ratio, Return on Invested Capital, PEG Ratio. Each blank in the table above names the rest, with its reason. 3 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map
  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.